Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nina Bhardwaj
Icahn School of Medicine at Mount Sinai, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
CheckPoint Sciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Nina Bhardwaj (a Co-Investigator in this study) owns shares of CheckPoint Sciences (CPS) (a privately-held company, focused on commercializing response-predictive biomarkers that will facilitate the adoption and use of cancer immunotherapy in a clinically effective and cost-efficient manner). CPS and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai have established a collaboration that makes bioinformatics services available to pharmaceutical and biotech companies to facilitate the development of companion diagnostics for specific cancer immunotherapies. You may ask Dr. Bhardwaj any questions necessary to assure yourself that this financial relationship does not influence her conduct of this research study.
Patient-Specific Mutation-Derived Tumor Neoantigens as Targets for Cancer Immunotherapy in Smoldering Multiple Myeloma
Project Narrative Multiple myeloma (MM) is a multi-stage disease affecting >30,000 new patients every year. MM begins as a slowly progressing disease without obvious symptoms. An early stage of the disease is smoldering MM (SMM), which invariably progresses to MM over time. The risk of progression for SMM patients to active MM is 10% or higher per year, and there are no approved therapies for SMM. Using a combination of genetic sequencing and computational predictions of the mutant protein expression of each patient's cancer, we have developed a pipeline to identify patient-specific mutations that can be exploited by the immune system to fight their MM. Our clinic sees over 80 SMM patients per year and we have several ongoing trials studying immune checkpoint inhibitors in relapsed MM. We will conduct an in-depth analysis of SMM tumor immunology including neo-antigenic landscape and T cell responsiveness. Our study will provide the basis for future trials using personalized vaccines and immune checkpoint inhibitors in patients with SMM.
Filed on May 06, 2019.
Tell us what you know about Nina Bhardwaj's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.